Table 3.
Sensitivity analysis
| Increased odds of NCCRT (vs. esophagectomy) by unmeasured confounder (%) | Upper end of P value† for negative INB when WTP = US$150,000 |
|---|---|
| 1.0 | 0.044 |
| 1.5 | 0.046 |
| 2.0 | 0.048 |
| 2.5 | 0.049 |
| 3.0 | 0.051 |
| 3.5 | 0.053 |
Rounded at the third decimal. ICER: incremental cost‐effectiveness ratio; INB, incremental net benefit; NCCRT, neoadjuvant concurrent chemoradiotherapy; WTP, willingness‐to‐pay (in United States dollars/life‐year).